These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Metastatic neuroendocrine tumor of unknown primary presenting as acute pancreatitis. Dhar S; Grossman CE; Kokroo T Am J Med Sci; 2008 Apr; 335(4):304-6. PubMed ID: 18414070 [TBL] [Abstract][Full Text] [Related]
23. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site. Hainsworth JD; Johnson DH; Greco FA Cancer; 1991 Jan; 67(1 Suppl):310-4. PubMed ID: 1984833 [TBL] [Abstract][Full Text] [Related]
24. [Clinicopathologic features of primary renal neuroendocrine carcinoma]. Wang XH; Lu X; He B; Jiang YX; Yu WJ; Wang H; Zhang W; Li YJ Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):851-856. PubMed ID: 30423609 [No Abstract] [Full Text] [Related]
25. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. Xu B; Scognamiglio T; Cohen PR; Prasad ML; Hasanovic A; Tuttle RM; Katabi N; Ghossein RA Hum Pathol; 2017 Jul; 65():133-139. PubMed ID: 28552827 [TBL] [Abstract][Full Text] [Related]
26. [Metastases to the breast from non-mammary malignancies: a clinicopathologic study of 28 cases]. Zhou S; Yu B; Cheng Y; Xu X; Shui R; Bi R; Lu H; Tu X; Yang W Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):231-5. PubMed ID: 24915812 [TBL] [Abstract][Full Text] [Related]
27. Diagnosis and management of metastatic neoplasms with unknown primary. Bochtler T; Löffler H; Krämer A Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116 [TBL] [Abstract][Full Text] [Related]
28. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Cloyd JM; Yang RL; Allison KH; Norton JA; Hernandez-Boussard T; Wapnir IL Breast Cancer Res Treat; 2014 Dec; 148(3):637-44. PubMed ID: 25399232 [TBL] [Abstract][Full Text] [Related]
29. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Lazaridis G; Pentheroudakis G; Fountzilas G; Pavlidis N Cancer Treat Rev; 2008 Dec; 34(8):693-700. PubMed ID: 18584969 [TBL] [Abstract][Full Text] [Related]
30. A case of long-term recurrence-free poorly differentiated neuroendocrine carcinoma of lymph nodes treated by surgical resection without any chemotherapy. Hisamori S; Okabe H; Yoshizawa A; Sakai Y Int J Clin Oncol; 2010 Oct; 15(5):493-6. PubMed ID: 20224882 [TBL] [Abstract][Full Text] [Related]
32. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India. Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245 [TBL] [Abstract][Full Text] [Related]
33. [Electron microscopy of needle biopsies from cancer patients with unknown primary tumors]. Horn T; Andersen CB; Nerstrøm H Ugeskr Laeger; 1993 Apr; 155(15):1126-9. PubMed ID: 8488599 [TBL] [Abstract][Full Text] [Related]
34. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793 [TBL] [Abstract][Full Text] [Related]
35. [Unknown primary cancer]. Furue H Gan To Kagaku Ryoho; 1998 Jan; 25(1):1-6. PubMed ID: 9464322 [TBL] [Abstract][Full Text] [Related]